In the News
Rakesh Jain Inducted into the National Academy of Fellows
“Deciphering and targeting mechanisms involved in resistance to anti-angiogenic therapy is critical to realizing the full potential of this promising cancer therapy,” says Dai Fukumura, MD, PhD, deputy director of the Steele Labs, co-senior author of the paper. “Not only is this the first report investigating the role in anti-angiogenic cancer therapy of a subset of innate immune cells – Ly6Clowor non-classical monocytes – it is also the first to find an immunosuppressive function for these cells and to identify that as the key mechanism conferring resistance to anti-angiogenic therapy.”
"What did the lymph nodes show?" is the question whose answer is apprehensively awaited by every colon cancer patient. Even in the age of molecular medicine, the absence or presence of colon cancer spread to regional lymph nodes remains the strongest predictor of whether surgery has cured the cancer, or whether an individucal may harbor occult metastatic disease and thus require adjuvant chemotherapy to reduce the risk of lethal cancer metastasese recurring in distant organs.